secwatch.observer — SEC 8-K summary
======================================

Issuer:     Actinium Pharmaceuticals, Inc. (ATNM)
CIK:        0001388320
Form:       8-K
Filed at:   2022-04-13T23:59:59+00:00
Accession:  0001213900-22-019512
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Actinium licenses Iomab-B to Immedica for $35M upfront plus up to $417M milestones
--------------------------------------------------------------------------------

- Upfront payment of $35 million from Immedica upon signing.
- Eligible for aggregate regulatory/commercial milestones up to ~$417 million.
- Royalties in mid-20% range on net sales in certain countries in licensed territory.
- Immedica gets exclusive rights in EUMENA; Actinium retains U.S. and rest-of-world rights.
- Actinium continues to handle clinical development and manufacturing of Iomab-B.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1388320/000121390022019512/0001213900-22-019512-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1388320/000121390022019512/ea158381-8k_actinium.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-019512

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer